A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade

The topoisomerase enzymes play an important role in DNA metabolism, and searching for enzyme inhibitors is an important target in the search for new anticancer drugs. Discovery of new anticancer chemotherapeutical capable of inhibiting topoisomerase enzymes is highlighted in anticancer research. The...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of medicinal chemistry 2019-06, Vol.171, p.129-168
Hauptverfasser: Liang, Xiaoxia, Wu, Qiang, Luan, Shangxian, Yin, Zhongqiong, He, Changliang, Yin, Lizi, Zou, Yuanfeng, Yuan, Zhixiang, Li, Lixia, Song, Xu, He, Min, Lv, Cheng, Zhang, Wei
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 168
container_issue
container_start_page 129
container_title European journal of medicinal chemistry
container_volume 171
creator Liang, Xiaoxia
Wu, Qiang
Luan, Shangxian
Yin, Zhongqiong
He, Changliang
Yin, Lizi
Zou, Yuanfeng
Yuan, Zhixiang
Li, Lixia
Song, Xu
He, Min
Lv, Cheng
Zhang, Wei
description The topoisomerase enzymes play an important role in DNA metabolism, and searching for enzyme inhibitors is an important target in the search for new anticancer drugs. Discovery of new anticancer chemotherapeutical capable of inhibiting topoisomerase enzymes is highlighted in anticancer research. Therefore, biologists, organic chemists and medicinal chemists all around the world have been identifying, designing, synthesizing and evaluating a variety of novel bioactive molecules targeting topoisomerase. This review summarizes types of topoisomerase inhibitors in the past decade, and divides them into nine classes by structural characteristics, including N-heterocycles compounds, quinone derivatives, flavonoids derivatives, coumarin derivatives, lignan derivatives, polyphenol derivatives, diterpenes derivatives, fatty acids derivatives, and metal complexes. Then we discussed the application prospect and development of these anticancer compounds, as well as concluded parts of their structural-activity relationships. We believe this review would be invaluable in helping to further search potential topoisomerase inhibition as antitumor agent in clinical usage. [Display omitted] •Topoisomerase inhibitors were primarily classified into nine structural classes.•Some exhibited exciting biological results better than the first line treatments.•Topo IIα inhibitors are more favorable than topo IIβ, but still with toxic to normal cells.•The mechanism of action needs further research.•The selectivity on the target and the in vivo tests should be focused on.
doi_str_mv 10.1016/j.ejmech.2019.03.034
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2199182595</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0223523419302521</els_id><sourcerecordid>2199182595</sourcerecordid><originalsourceid>FETCH-LOGICAL-c428t-67940d96290041df7f721cd5180073cc7eafbef12232aa12bf8aca92df4c9223</originalsourceid><addsrcrecordid>eNp9kEtrWzEQhUVpaJzHPyhFy26uO3rchzYFE5I0YOgmq2yELI1qGd-rW0l2yb-PjNMuCwcGZs7MYT5CPjNYMmDdt90SdyPa7ZIDU0sQVfIDWbC-GxrBW_mRLIBz0bRcyEtylfMOANoO4BO5FKBYL0AsyMuK2jjOCbc45XBEmvAY8A-NnpY4x5DjiMlkpGHahk0oMWVqqqYSrJksJmp-4VRyndOyRTqbXKhDaxzekAtv9hlv3-s1eX64f7770ax_Pj7drdaNlXwoTdcrCU51XAFI5nzve86sa9kA0AtrezR-g57VX7gxjG_8YKxR3HlpVW1ek6_ns3OKvw-Yix5DtrjfmwnjIWvOlGIDb1VbrfJstSnmnNDrOYXRpFfNQJ-g6p0-Q9UnqBpElaxrX94TDpsR3b-lvxSr4fvZgPXNii_pbANWOi4ktEW7GP6f8AYRk4qx</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2199182595</pqid></control><display><type>article</type><title>A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade</title><source>Elsevier ScienceDirect Journals</source><creator>Liang, Xiaoxia ; Wu, Qiang ; Luan, Shangxian ; Yin, Zhongqiong ; He, Changliang ; Yin, Lizi ; Zou, Yuanfeng ; Yuan, Zhixiang ; Li, Lixia ; Song, Xu ; He, Min ; Lv, Cheng ; Zhang, Wei</creator><creatorcontrib>Liang, Xiaoxia ; Wu, Qiang ; Luan, Shangxian ; Yin, Zhongqiong ; He, Changliang ; Yin, Lizi ; Zou, Yuanfeng ; Yuan, Zhixiang ; Li, Lixia ; Song, Xu ; He, Min ; Lv, Cheng ; Zhang, Wei</creatorcontrib><description>The topoisomerase enzymes play an important role in DNA metabolism, and searching for enzyme inhibitors is an important target in the search for new anticancer drugs. Discovery of new anticancer chemotherapeutical capable of inhibiting topoisomerase enzymes is highlighted in anticancer research. Therefore, biologists, organic chemists and medicinal chemists all around the world have been identifying, designing, synthesizing and evaluating a variety of novel bioactive molecules targeting topoisomerase. This review summarizes types of topoisomerase inhibitors in the past decade, and divides them into nine classes by structural characteristics, including N-heterocycles compounds, quinone derivatives, flavonoids derivatives, coumarin derivatives, lignan derivatives, polyphenol derivatives, diterpenes derivatives, fatty acids derivatives, and metal complexes. Then we discussed the application prospect and development of these anticancer compounds, as well as concluded parts of their structural-activity relationships. We believe this review would be invaluable in helping to further search potential topoisomerase inhibition as antitumor agent in clinical usage. [Display omitted] •Topoisomerase inhibitors were primarily classified into nine structural classes.•Some exhibited exciting biological results better than the first line treatments.•Topo IIα inhibitors are more favorable than topo IIβ, but still with toxic to normal cells.•The mechanism of action needs further research.•The selectivity on the target and the in vivo tests should be focused on.</description><identifier>ISSN: 0223-5234</identifier><identifier>EISSN: 1768-3254</identifier><identifier>DOI: 10.1016/j.ejmech.2019.03.034</identifier><identifier>PMID: 30917303</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Anticancer compounds ; Antiproliferative activity ; Topoisomerase inhibitor</subject><ispartof>European journal of medicinal chemistry, 2019-06, Vol.171, p.129-168</ispartof><rights>2019 Elsevier Masson SAS</rights><rights>Copyright © 2019 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c428t-67940d96290041df7f721cd5180073cc7eafbef12232aa12bf8aca92df4c9223</citedby><cites>FETCH-LOGICAL-c428t-67940d96290041df7f721cd5180073cc7eafbef12232aa12bf8aca92df4c9223</cites><orcidid>0000-0001-5002-5327 ; 0000-0003-1752-644X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0223523419302521$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30917303$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liang, Xiaoxia</creatorcontrib><creatorcontrib>Wu, Qiang</creatorcontrib><creatorcontrib>Luan, Shangxian</creatorcontrib><creatorcontrib>Yin, Zhongqiong</creatorcontrib><creatorcontrib>He, Changliang</creatorcontrib><creatorcontrib>Yin, Lizi</creatorcontrib><creatorcontrib>Zou, Yuanfeng</creatorcontrib><creatorcontrib>Yuan, Zhixiang</creatorcontrib><creatorcontrib>Li, Lixia</creatorcontrib><creatorcontrib>Song, Xu</creatorcontrib><creatorcontrib>He, Min</creatorcontrib><creatorcontrib>Lv, Cheng</creatorcontrib><creatorcontrib>Zhang, Wei</creatorcontrib><title>A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade</title><title>European journal of medicinal chemistry</title><addtitle>Eur J Med Chem</addtitle><description>The topoisomerase enzymes play an important role in DNA metabolism, and searching for enzyme inhibitors is an important target in the search for new anticancer drugs. Discovery of new anticancer chemotherapeutical capable of inhibiting topoisomerase enzymes is highlighted in anticancer research. Therefore, biologists, organic chemists and medicinal chemists all around the world have been identifying, designing, synthesizing and evaluating a variety of novel bioactive molecules targeting topoisomerase. This review summarizes types of topoisomerase inhibitors in the past decade, and divides them into nine classes by structural characteristics, including N-heterocycles compounds, quinone derivatives, flavonoids derivatives, coumarin derivatives, lignan derivatives, polyphenol derivatives, diterpenes derivatives, fatty acids derivatives, and metal complexes. Then we discussed the application prospect and development of these anticancer compounds, as well as concluded parts of their structural-activity relationships. We believe this review would be invaluable in helping to further search potential topoisomerase inhibition as antitumor agent in clinical usage. [Display omitted] •Topoisomerase inhibitors were primarily classified into nine structural classes.•Some exhibited exciting biological results better than the first line treatments.•Topo IIα inhibitors are more favorable than topo IIβ, but still with toxic to normal cells.•The mechanism of action needs further research.•The selectivity on the target and the in vivo tests should be focused on.</description><subject>Anticancer compounds</subject><subject>Antiproliferative activity</subject><subject>Topoisomerase inhibitor</subject><issn>0223-5234</issn><issn>1768-3254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kEtrWzEQhUVpaJzHPyhFy26uO3rchzYFE5I0YOgmq2yELI1qGd-rW0l2yb-PjNMuCwcGZs7MYT5CPjNYMmDdt90SdyPa7ZIDU0sQVfIDWbC-GxrBW_mRLIBz0bRcyEtylfMOANoO4BO5FKBYL0AsyMuK2jjOCbc45XBEmvAY8A-NnpY4x5DjiMlkpGHahk0oMWVqqqYSrJksJmp-4VRyndOyRTqbXKhDaxzekAtv9hlv3-s1eX64f7770ax_Pj7drdaNlXwoTdcrCU51XAFI5nzve86sa9kA0AtrezR-g57VX7gxjG_8YKxR3HlpVW1ek6_ns3OKvw-Yix5DtrjfmwnjIWvOlGIDb1VbrfJstSnmnNDrOYXRpFfNQJ-g6p0-Q9UnqBpElaxrX94TDpsR3b-lvxSr4fvZgPXNii_pbANWOi4ktEW7GP6f8AYRk4qx</recordid><startdate>20190601</startdate><enddate>20190601</enddate><creator>Liang, Xiaoxia</creator><creator>Wu, Qiang</creator><creator>Luan, Shangxian</creator><creator>Yin, Zhongqiong</creator><creator>He, Changliang</creator><creator>Yin, Lizi</creator><creator>Zou, Yuanfeng</creator><creator>Yuan, Zhixiang</creator><creator>Li, Lixia</creator><creator>Song, Xu</creator><creator>He, Min</creator><creator>Lv, Cheng</creator><creator>Zhang, Wei</creator><general>Elsevier Masson SAS</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5002-5327</orcidid><orcidid>https://orcid.org/0000-0003-1752-644X</orcidid></search><sort><creationdate>20190601</creationdate><title>A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade</title><author>Liang, Xiaoxia ; Wu, Qiang ; Luan, Shangxian ; Yin, Zhongqiong ; He, Changliang ; Yin, Lizi ; Zou, Yuanfeng ; Yuan, Zhixiang ; Li, Lixia ; Song, Xu ; He, Min ; Lv, Cheng ; Zhang, Wei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c428t-67940d96290041df7f721cd5180073cc7eafbef12232aa12bf8aca92df4c9223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Anticancer compounds</topic><topic>Antiproliferative activity</topic><topic>Topoisomerase inhibitor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liang, Xiaoxia</creatorcontrib><creatorcontrib>Wu, Qiang</creatorcontrib><creatorcontrib>Luan, Shangxian</creatorcontrib><creatorcontrib>Yin, Zhongqiong</creatorcontrib><creatorcontrib>He, Changliang</creatorcontrib><creatorcontrib>Yin, Lizi</creatorcontrib><creatorcontrib>Zou, Yuanfeng</creatorcontrib><creatorcontrib>Yuan, Zhixiang</creatorcontrib><creatorcontrib>Li, Lixia</creatorcontrib><creatorcontrib>Song, Xu</creatorcontrib><creatorcontrib>He, Min</creatorcontrib><creatorcontrib>Lv, Cheng</creatorcontrib><creatorcontrib>Zhang, Wei</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liang, Xiaoxia</au><au>Wu, Qiang</au><au>Luan, Shangxian</au><au>Yin, Zhongqiong</au><au>He, Changliang</au><au>Yin, Lizi</au><au>Zou, Yuanfeng</au><au>Yuan, Zhixiang</au><au>Li, Lixia</au><au>Song, Xu</au><au>He, Min</au><au>Lv, Cheng</au><au>Zhang, Wei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade</atitle><jtitle>European journal of medicinal chemistry</jtitle><addtitle>Eur J Med Chem</addtitle><date>2019-06-01</date><risdate>2019</risdate><volume>171</volume><spage>129</spage><epage>168</epage><pages>129-168</pages><issn>0223-5234</issn><eissn>1768-3254</eissn><abstract>The topoisomerase enzymes play an important role in DNA metabolism, and searching for enzyme inhibitors is an important target in the search for new anticancer drugs. Discovery of new anticancer chemotherapeutical capable of inhibiting topoisomerase enzymes is highlighted in anticancer research. Therefore, biologists, organic chemists and medicinal chemists all around the world have been identifying, designing, synthesizing and evaluating a variety of novel bioactive molecules targeting topoisomerase. This review summarizes types of topoisomerase inhibitors in the past decade, and divides them into nine classes by structural characteristics, including N-heterocycles compounds, quinone derivatives, flavonoids derivatives, coumarin derivatives, lignan derivatives, polyphenol derivatives, diterpenes derivatives, fatty acids derivatives, and metal complexes. Then we discussed the application prospect and development of these anticancer compounds, as well as concluded parts of their structural-activity relationships. We believe this review would be invaluable in helping to further search potential topoisomerase inhibition as antitumor agent in clinical usage. [Display omitted] •Topoisomerase inhibitors were primarily classified into nine structural classes.•Some exhibited exciting biological results better than the first line treatments.•Topo IIα inhibitors are more favorable than topo IIβ, but still with toxic to normal cells.•The mechanism of action needs further research.•The selectivity on the target and the in vivo tests should be focused on.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>30917303</pmid><doi>10.1016/j.ejmech.2019.03.034</doi><tpages>40</tpages><orcidid>https://orcid.org/0000-0001-5002-5327</orcidid><orcidid>https://orcid.org/0000-0003-1752-644X</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0223-5234
ispartof European journal of medicinal chemistry, 2019-06, Vol.171, p.129-168
issn 0223-5234
1768-3254
language eng
recordid cdi_proquest_miscellaneous_2199182595
source Elsevier ScienceDirect Journals
subjects Anticancer compounds
Antiproliferative activity
Topoisomerase inhibitor
title A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T12%3A22%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20comprehensive%20review%20of%20topoisomerase%20inhibitors%20as%20anticancer%20agents%20in%20the%20past%20decade&rft.jtitle=European%20journal%20of%20medicinal%20chemistry&rft.au=Liang,%20Xiaoxia&rft.date=2019-06-01&rft.volume=171&rft.spage=129&rft.epage=168&rft.pages=129-168&rft.issn=0223-5234&rft.eissn=1768-3254&rft_id=info:doi/10.1016/j.ejmech.2019.03.034&rft_dat=%3Cproquest_cross%3E2199182595%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2199182595&rft_id=info:pmid/30917303&rft_els_id=S0223523419302521&rfr_iscdi=true